

INDEX

Note: HF stands for heart failure.

Page numbers in *italics* indicate figures.

Page numbers followed by a “t” indicate tables.

Clinical trials and studies are indexed under the acronym of the name.

- 6-minute walk test, 40, 195, 196, 200, 226, 242, 249
- A-type natriuretic peptide (ANP), 51, 88
- ACC/AHA
guidelines for heart failure management, xvi-xviii[t], 258
stages of heart failure, 40-43, 41t
relationship to NYHA classification, 42
- ACE inhibitors. See *ACEi-s*.
- ACEi-s (angiotensin-converting enzyme (ACE) inhibitors), 83-86
action mechanisms, 83, 84
adverse effects, 86t
ARBs vs, 83-84, 87-88
cautions/contraindications, xv, xviii, 86t
clinical trials, 87-88
CHARM, 87-88
CONSENSUS, 84
ONTARGET, 87
SOLVD, 84
efficacy, 84, 87
indications for
HF-rEF patients, xviii, 84
HF with CKD, 194t
kinins and, 84
switching to an ARB, 86-87
switching to sacubitril/valsartan, 91, 94
- Acute coronary syndrome (ACS), 128
- Acute decompensated heart failure (ADHF), 253-277
classification of patients, 255, 258
cold and dry, 39t, 255, 258
cold and wet, 258
cold, cardiac output in, 257t
cold, treatment decisions for, 255
hemodynamic patterns, 39t

Acute decompensated heart failure (ADHF), classification of patients (*continued*)
pulmonary congestion (“wet”), 256t
treatment decisions and, 255
volume status for “wet” vs “dry”, 32t, 259
warm and dry, 255, 258
warm and wet, 39t, 258
clinical presentation, 254-255, 256t-257t
low cardiac output (“cold”), 257t
overall circulatory assessment, 255, 258
pulmonary or systemic congestion (“wet”), 256t
decompensation as sentinel prognostic event, 253
goals of therapy, 255
hemodynamic deterioration
as marker for high risk of adverse outcomes, 264-266
number of hospitalizations, mortality risk and, 253-254, 254
preceding clinical events, 253
heterogeneity in ADHF population, 253, 274
in HF-pEF patients, 253
in HF-rEF patients, 253
hospitalization for, 34, 34, 253-254
EVEREST study, 254
mortality risk and, 253-254, 254
number of HF hospitalizations and, 254, 254
initial evaluation, 255, 258t
medical management
challenges in, 274-275
diuretics, 259-260
goals of therapy, 255
heterogeneity in ADHF population, 253, 274
individualization of, 255, 274
initial evaluation and, 255, 258
summary and evaluation, 274-275
symptomatic relief, 258-274. See also *specific agents listed under symptomatic relief, below.*
new-onset, 253
population characteristics, 253
precipitating factors, 255, 259t
prevalence of, 253
signs and symptoms, 254-255, 256t-257t

Acute decompensated heart failure (ADHF) (*continued*)
symptomatic relief, agents for, 258-274
diuretics, 259-260, 261, 274
dobutamine, 267t
dopamine, 266-274, 267t
vs nesiritide, 266-274, 270-273
inotropes, 266-274, 267t
not recommended for HF-rEF patients with ADHF, 266
milrinone, 266, 267t
adverse events with, 266, 268t-269t
morphine, 258-259
nesiritide, 264, 265t
vs dopamine, 266-274, 270-273
summary and evaluation of, 274-275
ultrafiltration, 262, 274
vasodilators, 262-266, 274
blood pressure and, 264, 265t
vasopressin antagonists, 260-262, 263
Acute heart failure, 22t, 44t. See also *Acute decompensated heart failure (ADHF).*
Acutely decompensated HF (ADHF), 34, 39-40
ADHF. See *Acute decompensated heart failure.*
Adrenergic agonists, 266-274, 267t
Adrenergic blockers. See *β-blockers.*
Advanced HF, INTERMACS registry of stages for, 242, 244t-245t, 248
Afterload, 50
Air pollution, 79
Albuminuria, 61, 186
Alcohol intake, 74-76, 75
Aldactone. See *Spironolactone.*
Aldosterone, 102
Aldosterone antagonists, 102. See also *Eplerenone; Spironolactone.*
agents, 102
eplerenone, 102
spironolactone, 102
Alogliptin, 165t
Alpha glucosidase inhibitors, 165t
Altitude, 78
Alzheimer’s disease, comorbid with HF, 160t
American College of Cardiology/American Heart Association. See *ACC/AHA.*

Amiodarone, 143

Anemia, 66, 193-195
 comorbid with HF, 160t, 162t, 193-195
 iron deficiency, 193, 201, 202
 iron supplementation treatments, 194-195, 196-200

Angina, 36t, 46, 171

Angioedema
 as ACE-i side effect, 86t
 contraindication for sacubitril/valsartan, xv, 89
 minimizing risk for, xviii
 prior, as medication contraindication, 86t

Angiotensin, 50, 183. See also *Renin-angiotensin-aldosterone system*.

Angiotensin I, 85
 conversion to angiotensin II, 85

Angiotensin II, 85

Angiotensin II receptor blockers. See *ARBs*.

Angiotensin-converting enzyme (ACE) inhibitors.
 See *ACEi-s*.

Angiotensin receptor neprilysin inhibitor (ARNI), xv, 88.
 See also *Sacubitril/valsartan*.

Anti-platelet agents, 125-127

Anti-thrombotic agents, 125-131

Anti-Xa anticoagulants, 127-128

Antibiotics, 154-155

Anticoagulants, 127-131
 anti-Xa anticoagulants, 127-128
 clinical trials
 ATLAS-2, 131
 COMMANDER-HF, 130-131
 HF and AF, 127-128
 HF with AF and CAD, 128-130
 HF without AF, 130-131
 implantable devices and, 152, 153
 indications for, 127-128
 oral, use with clopidogrel, 130
 triple therapy, 129
 warfarin, 127, 128

Antidepressants, xx, 287
 SSRIs, xix-xx, 287
 tricyclic, xx

Aortic stenosis, 217-219, 218
 approved TAVR systems, 218-219
 decision making for TAVR patients, 224
 Edwards Sapien transcatheter valve system, 218
 Medtronic Evolut R System, 218
 post-procedure improvements, 220-223

ARBs (angiotensin II receptor blockers), 83-84, 86-88
 ACEi-s vs, 83-84, 88
 action mechanisms, 83-84
 adverse effects, 86, 86t
 ARBs, 83-84, 86-88
 cautions/contraindications, 86t
 combining sacubitril/valsartan with, xv, xviii
 clinical trials, PARAMOUNT trial, 60-61
 discontinuation of, 87
 dosage of, switching from ACEi to, 86-87
 efficacy, 87-88
 indications for, xix, 86-88
 HF-pEF, 88
 HF-rEF, 88
 HF with CKD, 194t
 switching to sacubitril/valsartan, 91, 94
 tolerability, 86

Arginine vasopressin, 260
 vasopressin antagonists, 260-262, 263

ARNI (angiotensin receptor neprilysin inhibitor), xv, 88.
 See also *Sacubitril/valsartan*.
 PARAMOUNT trial, 60-61

Arrhythmia. See *Atrial fibrillation*.

Arthritis, comorbid with HF, 160t

ASCEND-HF, 264, 265t, 274

Aspirin, 129

Asthma, 160t, 162t

ATLAS-2 trial, 131

Atrial fibrillation (AF), 26t, 127-131
 ADHF precipitated by, 259t
 anticoagulants. See also *Anticoagulants*.
 contraindication for, 228-229, 231
 Watchman Device as alternative, 229-231, 230
 cardiac resynchronization therapy (CRT) for, 147-151
 cognitive impairment and, 282-283, 284-285
 heart failure plus CAD with, 128-130

- Atrial fibrillation (AF) (*continued*)
heart failure with, 127-128, 160t
heart failure without AF, 130-131
incidence in HF patients, 228
management of, left atrial appendage (LAA) closure,
228-231, 230
prevalence, 127, 128
progression of HF and, 35
stroke risk, 127
- Atrium, left. See *Left atrial appendage (LAA) closure*.
- AV nodal ablation, 147-151, 151
- Avandia (rosiglitazone)
- Azotemia, 86t
- B-type natriuretic peptide (BNP), 51, 88
increased, 256t
using to evaluate HF with COPD, 169, 179
- β -Blockers, 96-99
benefits of, xv
efficacy, 96-98
comparison of β -blockers, 98t
differences between β -blockers, 97, 98
in HF-pEF, 98-99
vs ivabradine, 99
indications for, 96, 98-99
HF patients with COPD, 169-173, 181t, 183t
in patients with HF-rEF, xviii
ivabradine and, xv
- Bile acid sequestrants, 165t
- Biomarkers, 25t
- Biopsy, endomyocardial, 31
- Bisoprolol
efficacy, 96
indications for, HF with CKD, 194t
- Blood glucose, 25t
- Blood pressure. See also *Hypertension; Hypotension*.
cognitive dysfunction and, 283
vasodilators and, 264, 265t
- Blood urea nitrogen (BUN), 25t
- BMI (body mass index), 23, 73
- Body mass index (BMI), 23, 73
- Bradykinin, 84
- Brain natriuretic peptide, diagnostic importance of, 25t
- Brain natriuretic peptide. See *B-type natriuretic peptide (BNP)*.
- Bromocriptine mesylate, 165t
- Bumetanide, 115
- BUN (blood urea nitrogen), 25t
- CABG surgery, 159-161
- Caloric restriction, 73-74
- Canagliflozin, 165t
- Cancer, 202-210
anti-HER2 and VEGF cardiotoxicity, 203, 210t
anticancer drugs and their CV effects, 206t-207t
cardiotoxic effects of anticancer agents, 202-203, 204-205
CV risk assessment, monitoring, and management
recommendations, 212t-213t
frequency, mechanism, and reversibility of cancer
therapies, 208t-209t
QT-prolongation, 203
radiation therapy, 203-210
signaling inhibitor agents, 203, 207t
- Candesartan, clinical trials of, 87-88, 186, 190-193, 192
- Canrenone, 106-107
- Cardiac catheterization. See *Catheterization*.
- Cardiac decompensation. See *Acute decompensated heart failure*.
- Cardiac output, 39t, 64, 111
assessment of, 31
in cardiogenic shock, 39t
decreased, cognitive dysfunction and, 283
in HF-pEF, 57
in HF-rEF, 54
low, 257t
preload/afterload in, 50
renal impairment and, 56t
- Cardiac resynchronization therapy (CRT), 143, 146,
148-149. See also *Pacing*.
in AF patients, 147-151
- Cardiac surgery. See *Surgical treatments*.
- Cardiac transplantation, 30, 31, 73, 237
- Cardio-oncology, 202-210. See also *Cancer*.
- Cardio-renal syndrome (CRS), 55, 55t

- Cardiogenic shock, 22t, 39t, 244t
 hemodynamic patterns in, 39t, 244t
 inotropes for, 274
- CardioMEMS HF System, 236-237
- Cardiopulmonary function testing, 29-30, 30t
- Cardiovascular history, 23, 23t
- Cardiovascular implantable electrophysiologic devices (CIEDs), 141-158. See also *Implantable hemodynamic monitoring*.
 anticoagulation, 152
 cardiac resynchronization therapy (CRT), 143, 146, 148-149
 in patients with AF, 147-151, 151
 CIED therapy and clinical management, 152
 dyssynchrony induced by RV pacing, 147, 150, 150t
 implantation of a new device, 155
 importance and summary, 153-156
 infection, 152-153
 treatment of, 154-155
 QRS widening, 143, 146
 sudden death, 141-143
- Cardioversion defibrillators, implanted, 141-143, 144-145
 ACC/AHA guidelines, 143
- CARESS trial, 262, 274
- Carvedilol, 96-97
 efficacy, 96
 indications for, HF with CKD, 194t
- Catheterization
 ESCAPE trial, 39
 left heart, for diagnosis, 30-31
 of right heart
 clinical outcomes and, 39
 diagnostic, 31
- CHAMPION trial, 236-237, 238-241
- CHARM, 87-88, 186, 190-193, 192
- Chemotherapy, 23t
 cardiotoxic effects, 202-203, 204-205
- Chest X-ray, 27-28
 information from, 27t
- Chlorpropamide, 165t
- Chlorthalidone, 113-115
 combined with MRA, 115
 compared with hydrochlorothiazide, 114t
- Chronic heart failure, 22t, 34, 44t. See also *Nonpharmacologic management of chronic heart failure*; *Pharmacologic management of heart failure*.
 acute exacerbation of, 35
 acute exacerbation, vs slowly progressing, 35
 nonpharmacologic management of, 71-82
 pharmacologic management of, 83-140
- Chronic kidney disease (CKD), 185-193
 ADHF precipitated by, 259t
 comorbid with HF, 159, 160t, 185-193
 impact for HF-pEF, 190-193, 191, 192
 impact for HF-rEF, 186, 187t, 189-190, 192, 193
 Kaplan-Meier plots, 186, 188, 191, 192
 management principles, 193, 194t
 negative feedback cycle in, 186, 189
 prevalence and severity of hospital admissions, 189, 190
 prevalence of coexisting CKD in HF population, 186-189, 190
 definition and pathophysiology, 185-186
 GFR in, 185, 186
 MDRD formula, 185, 186
 prevalence in general population, 187t
 prevalence of in HF population, 186-189, 190
 in HF-rEF patients, 187t
- Chronic obstructive pulmonary disease (COPD), 35, 60, 66, 169-185
 comorbid with HF, 159, 160t, 162t, 169-185
 β -blockers for, 169-173, 181t, 183t
 ivabradine for heart rate reduction, 173-179, 184t, 185
 recommended therapies, 173, 180
 using B-type natriuretic peptide levels to evaluate, 169, 179
 heart failure and, 37t, 60, 169-185
 HF-pEF and, 60, 66
 HF-rEF and, 173-179
 prevalence in HF population, 169
 SHIFT trial, 173-175, 182t-184t
- Chronic pulmonary hypertension, 60
- Chronic thromboembolic pulmonary hypertension (CTEPH), 38
- Chronotropic incompetence, 54, 68t, 99
- CIEDs. See *Cardiovascular implantable electrophysiologic devices*.

Circulatory support, mechanical, 237-246
Classification of heart failure, 33-47
ACC/AHA stages of heart failure, 40-43, 41t, 42
acute HF, 34, 44t
acutely decompensated HF (ADHF), 34, 39-40, 255, 258
based on anatomy and function, 35-40, 38, 44t
hemodynamic patterns, 39-40, 39t
HF-rEF, 38-39
left heart failure, 38-39, 38
right ventricular failure, 35-38, 38
based on timing of symptoms, 34, 44t
acute vs chronic, 34, 44t
chronic HF, 34, 44t
acute exacerbation, vs slowly progressing, 35
comorbid processes and, 35
demographic data, 36t-37t
heart failure syndromes, classification of, 35-39
NYHA classification, 40-43, 40, 41t, 42
phenotypes of HF patients, 43, 46-47
treatment context provided by, 43, 44t
Clinical syndromes and staging of HF, 33-47. See also
Classification of heart failure.
Clinical trials. See *specific agents, treatments, and specific trials by name.*
Clopidogrel, 130
Coenzyme Q10, 76
Cognitive impairment, 282-283, 284-285
atrial fibrillation and, 282-283, 284-285
dementia, 160t, 282
ESC Guideline recommendations on, 281t
silent cerebral ischemia (SCI), 282, 283
Colesevelam, 165t
COMMANDER-HF, 130-131
Comorbid conditions, 36t-37t, 49, 159-216. See also
specific conditions, eg, Diabetes mellitus.
Alzheimer's disease/dementia, 160t, 282
anemia, 160t, 162t, 193-195
arthritis, 160t
asthma, 160t, 162t
atrial fibrillation, 127-128, 160t
cancer, 202-210
cardiovascular conditions and risk factors, 36t

Comorbid conditions (*continued*)
challenges to HF management, 159
chronic kidney disease (CKD), 159, 160t, 185-193
commonly associated with HF, 159, 160t, 162t-163t
COPD, 159, 160t, 162t, 169-185
coronary artery disease (CAD), 159-161
depression, 160t, 283-288
diabetes, 159, 160t, 161-169, 162t, 165t
geriatric conditions, 37t
HF and atrial fibrillation, 127-128
with CAD, 128-130
HF-pEF and, 49, 66-67
COPD, 60
hyperlipidemia, 160t
hypertension, 36t, 160t
ischemic heart disease, 160t
obesity, 162t
other medical conditions, 37t
progression of HF and, 35
psychosocial conditions, 37t
COMPASS-HF trial, 231-236
Computed tomography (CT)
CONFIRM-HF study, 195, 202
Congestion, pulmonary or systemic, 255, 256t, 258
CONSENSUS trial, 83
Contrast ventriculography, 30
COPD. See *Chronic obstructive pulmonary disease.*
Cordarone (amiodarone), 143
Corlanor. See *Ivabradine.*
Coronary angiography, 30-31
Coronary artery disease (CAD), 159-161
CABG surgery, 159-161
heart failure and, 36t, 159-161
heart failure and AF with, 129-130
Coronary disease, progression of, 35
Cough, ACE inhibitors and, 86t
CTEPH (chronic thromboembolic pulmonary hypertension), 38
Dapagliflozin, 165t
Decompensated heart failure. See *Acute decompensated heart failure (ADHF).*

Decompensation, as sentinel prognostic event, 253

Defibrillators: implantable cardioverter-debibrillators, 141-143, *144-145*

Depression, xix-xx, 283-288

- adherence to therapy and, xix
- antidepressants, xx, 287
- clinical trials on, 287
- cognitive behavioral therapy, xix
- ESC Guideline recommendations on, 281t
- evaluation instruments, 287
- exercise and, 287-288
- heart failure and, 37t, 160t, 283
 - HF-rEF, 287-288
- HF prognosis and, 283, 286
- hospitalizations and mortality and, 283-287, 286
- prevalence of, 283
- screening for, xix
- SSRIs for, xix-xx, 287
- worsening of symptoms, 287

Diabetes mellitus, 23t, 66, 161-169

- comorbid with HF, 159, 160t, 161-169, 162t
 - effects of anti-diabetic agents, 161-169
 - optimal management strategy, 169
 - potential adverse effects of anti-diabetic medications in HF, 161-169, *167, 176-177*
- heart failure and, 36t, 161-169
- heart failure treatment in, 159
- management of, 161-169, 165t
 - DPP-4 inhibitors, 165-166, 165t
 - efficacy data, review of, *170-172*
 - metformin, 165t, 166
 - SGLT2 inhibitors, 165t, 167-169, *168*
 - adverse effects, 169, *176-177*
 - CV outcomes trials, 178t
- type 1 diabetes, 161
- type 2 diabetes, 161-169
 - drugs used in treatment of, 161-169, 165t
 - efficacy data, review of, *170-172*

Diagnosis of heart failure, 21-32, 32t, 56. See also *Classification of heart failure; Clinical syndromes and staging*

- cardiac imaging studies, 28-29, 29t
 - 2D and Doppler echocardiography, 28, 28t

Diagnosis of heart failure, cardiac imaging studies (*continued*)

- comorbidities and, 29
- important data from, 28t
- chest X-ray, 27-28, 27t
- electrocardiogram (12-lead resting), 24-27, 26t
- exercise testing in, 30, 30t
- functional studies, 29-30, 30t
- history, 22-23
 - cardiovascular history, 23, 23t
- initial evaluation in ADHF patient, 255, 258t
- invasive studies, 30-31
 - cardiac catheterization, 30-31
 - contrast ventriculography, 30
 - coronary angiography, 30-31
 - endomyocardial biopsy, 31
 - right heart catheterization, 31
- laboratory tests, 23-24, 25t
- natriuretic peptides in, 25t
- outcomes of HF evaluation, 32t
- physical examination, 23, 24t
- presentation, 21, 22t, 43, 256t-257t
- salt and water retention, exercise intolerance, and dyspnea, 21, 22t

Diet, 71-77

- alcohol intake, 74-76, 75
- caloric restriction, 73-74
- dietary supplements, 76-77
 - coenzyme Q10, 76
 - nitrate supplementation, 76-77
- fluid restriction, 72
- sodium (salt) limitation, 71-72
 - clinical evidence for, 71
 - conversion factors, 72t
 - RAAS activation associated with, 71
 - summary of recommendations, 74t

DIG trial, 116-117, *126, 190, 191*

Digoxin, 116-117, *126*

- adverse effects, 116
- clinical trials of (DIG trial), 116-117, *126*
- indications for, 117
- monitoring of serum digoxin levels, 117
- risk ratio, 116-117

- Diuretics, 113-116. See also *specific agents*.
 adverse effects, 115
 agents
 chlorthalidone, 113-115, 114t
 furosemide, 33, 115, 122t-124t
 hydrochlorothiazide, 113, 114t
 torsemide, 115-116, 118-119, 120-121, 125t
 clinical trials, 113-115
 ALLHAT, 113
 DOSE, 259-260, 261, 274
 ROSE trial, 266-274, 270-273, 274
 combined with MRA, 115
 comparison of, 114t, 122t-124t, 125t
 continuous infusion with, 274
 dosage, low-dose vs. high-dose strategy in ADHF,
 259-260, 261
 efficacy, 113-116
 indications for, 113, 116
 in acute decompensated heart failure, 259-260, 261
 loop, 115-116
 thiazide, 113-115
 Dobutamine, 267t
 Dopamine, 266-274, 267t
 low-dose (“renal-dose”), to enhance effects of diuretics,
 266-274
 vs nesiritide (ROSE trial), 266-274, 270-273
 Dopamine receptor agonists, 165t
 Doppler echocardiography, 28, 28t
 DOSE trial, 259-260, 261, 274
 DPP-4 inhibitors, 165-166, 165t
 Dyspnea, 21, 22t, 56, 255, 256t
 nocturnal, 255
 vasodilators for, 262-264
 Edema, 255, 256t
 acute pulmonary, 39t, 43, 256t
 pulmonary edema, 22t, 43
 Ejection fraction. See also *Heart failure with preserved ejection fraction (HF-pEF)*; *Heart failure with reduced ejection fraction (HF-rEF)*.
 heart failure with mid-range ejection fraction (HF-mEF),
 xviii
 Ejection fraction (*continued*)
 heart failure with reduced ejection fraction (HF-rEF),
 xviii, 38-39
 treatment recommendations, xviii
 left ventricular (LVEF), 97, 110, 185
 in HF pathophysiology, 38
 treatment decisions and, xviii
 Elderly patients. See also *Psychosocial issues*.
 atrial fibrillation in, 127, 128
 cognitive impairment/dementia, 282-283
 frailty, 279-282
 heart failure in, 37t
 Electrocardiogram, 24-27, 26t
 12-lead, 24-27, 26t
 common findings in HF, 26t
 Electrolytes, 25t
 EMPA-REG OUTCOME, 174-175
 Empagliflozin, 165t
 Enalapril, 92-93, 189-190
 End-of-life planning, 288-291
 clinical indications for (ESC Guidelines), 288t
 management plan, discussing with patients and families,
 289-291, 290t
 palliative care, 288-289, 289
 suggestions for communication with patients, 289-291, 290t
 Endomyocardial biopsy, 31
 Endothelin receptor antagonists, 132t
 Entresto. See *Sacubitril/valsartan*.
 Environmental conditions, 78-79
 altitude, 78
 particulate pollution, 79
 temperature, 78-79
 Eplerenone, 102
 clinical trials, 103, 106-107
 EPHESUS, 103
 dosage, 104t-105t
 indications for, 103
 ESCAPE trial, 39, 55
 Escitalopram, xx
 EVEREST trials, 133, 260-262, 263, 274
 hospitalizations and future risk, 254

Exercise, 77, 287-288
cardiopulmonary exercise evaluation, 30t
clinical trials of, 287
depression, reduction in symptoms, 287-288
in HF-pEF, 77
in HF-rEF, 77
Exercise intolerance
in diagnosis, 21, 22t
onset of, 22-23
Exercise testing, 30, 30t

FAIR-HF study, 193-194, 195, 202
Familial heart disease, 22, 23t
Fibrillation, atrial. *See Atrial fibrillation.*
Filling pressures, 31, 39t, 50-51, 51, 57
in HF-pEF, 68t
Fluid restriction, 72
Fluid retention, 255, 256t. *See also Edema.*
FRAIL-HF study, 280-282
Frailty, 279-282
ADHF patients, 280-281
diagnosis of, 279-280
gait speed, 279-280
PRISMA-7 survey, 279-280
ESC guideline recommendations on, 280t
FRAIL-HF, 280-282
medication review, 280t
referral to specialist, 280t
Furosemide, 33, 115
vs torsemide, 122t-124t

Gender, hospitalization rates for HF and, 34, 35, 36t
GISSI-HF study, 76
Glimepiride, 165t
Glipizide, 165t
Glitazones, 165t
Glomerular filtration rate (GRF), 25t, 61, 104t-105t
Glyburide, 165t
Guidelines for heart failure management, xiv-xx
2013 ACCF/AHA Guideline, xiv
2016 ACC/AHA/HFSA, xiv-xv
2016 ESC Guidelines, xiv, xv-xx, 258-259

Guidelines for heart failure management (*continued*)
ACC/AHA recommendation system, xvi-xviii[t], 258
consensus view in, xx
critical information on, xiv
ESC Guidelines, xiv, xv-xx, 258-259
on psychosocial issues, 280t, 281t
guideline-directed therapy, xii, xiv
for ivabradine, xix, xv
level (quality) of evidence, xvii[t]
limitations of, xii
for sacubitril/valsartan, xv
strength/class of recommendations, xvi[t]
updates to, xiv-xx

Heart failure. *See also Treatment of heart failure.*
acute heart failure, 253-277
classification of, 33-47
clinical syndromes and staging, 33-47
comorbidities, 36t-37t, 159-216, 160t, 162t-163t
diagnosis of, 21-32
hemodynamic patterns in, 39-40, 39t
interventions for, 217-252
pathophysiology of, 49-69
psychosocial issues, 279-294
resources for patients, 295-296
subcategories of, 22t. *See also specific subcategories.*
heart failure with mid-range ejection fraction (HF-mEF),
xviii
heart failure with preserved ejection fraction (HF-pEF),
56-61
heart failure with reduced ejection fraction (HF-rEF),
xviii, 38-39
timing of: acute vs chronic, 22t
symptoms of, 21, 22t, 256t-257t
Heart failure with mid-range ejection fraction (HF-mEF),
xviii
Heart failure with preserved ejection fraction (HF-pEF), 44t
acute decompensated heart failure (ADHF) in, 253
comorbidities, 49, 66-67
chronic kidney disease (CKD), 190-193, 191, 192, 193
COPD, 60
definition of, 56-57

Heart failure with preserved ejection fraction (HF-pEF)
(continued)
 exercise recommendations, 77
 pathophysiology of, 56-61, 64
 cardiac changes, 68t
 comorbidities and, 49, 60, 66-67
 hypertension, 88
 musculoskeletal responses, 61, 68t
 pulmonary responses, 57-60, 68t
 renal responses, 60-61, 67
 phenotype, 43, 49
 physiology of (LV pressure/volume), 56-57, 62-63
 precapillary pulmonary hypertension and, 131-132
 treatment
 ACEi-s, 8
 ARBs, 8
 β -blockers, 98-99
 hydralazine/ISDN, 113
 MRAs, 106-109
 sacubitril/valsartan, 91

Heart failure with reduced ejection fraction (HF-rEF), 38-39, 44t
 acute decompensated heart failure (ADHF) in, 253
 comorbidities
 anemia, 195
 treatment algorithms, 201, 202
 chronic kidney disease (CKD), 186, 187t, 189-190, 192
 COPD, 173-179
 effectiveness of therapies, xviii, 49
 exercise recommendations, 77, 287-288
 pathophysiology in, 49-56
 CAD and, 161
 cardiovascular responses, 51-54, 52-53
 hemodynamic congestion, 50-51
 myocardial injury as initiator, 49, 50
 negative feedback cycles, 49-56, 50, 83-84
 pulmonary abnormalities, 54-55
 RAAS activation, 50, 50, 51, 51
 renal responses, 55-56, 55t, 56t
 salt and water retention, 50, 50
 treatment
 ACEi-s, xviii, 84-86

Heart failure with reduced ejection fraction (HF-rEF),
 treatment *(continued)*
 ARBs, 86-88
 β -blockers, xviii, 96
 digoxin, 117
 inotropes, 274
 ivabradine, 99
 MRAs, xviii, 102-106
 sacubitril/valsartan, 91

Heart rate
 CardioMEMS HF System for monitoring, 237
 in diagnosis, 24t, 26t
 elevated, 50
 inotropic agents and, 267t
 ivabradine for heart rate reduction, xix, 101, 173-179,
 184t, 185
 resting, 26t
 sympathetic nervous system and, 50

Heart rhythm, 26t

Heart transplant, 30, 31, 73, 237

HeartMate II device, 242, 243

Hemodynamics
 in acute decompensated heart failure
 deterioration, as marker for risk of adverse outcomes,
 264-266
 deterioration preceding clinical events, 253
 hemodynamic congestion, 50-51
 hemodynamic patterns in HF, 39-40, 39t
 in advanced HF, 244t-245t
 in cardiogenic shock, 39t, 244t
 implantable hemodynamic monitoring, 231-237
 vasodilator use and, 264-266, 265t

Hemoglobin/hematocrit, 25t

HF-ACTION Study, 287

HF-pEF. See *Heart failure with preserved ejection fraction.*

HF-rEF. See *Heart failure with reduced ejection fraction.*

History, in diagnosis, 22-23
 cardiovascular history, 23, 23t
 familial heart disease, 22, 23t

Hospitalization for heart failure
for acute decompensated heart failure (ADHF), 253-254, 254, 264-266, 265t
demographic data, 36t
discharges, number of, 34, 34
hospitalization rates, trends in, 34-35, 34, 36t
hospitalizations for depression, 283-287, 286
hypotension and, 264, 265t
mortality risk and, 253-254, 254, 264, 265t
before and after discharge, 254
number of HF hospitalizations and, 254, 254

Hydralazine, 109-113
action mechanism, 109-111
African Americans and, 111-113, 112
clinical trials of
A-HeFT, 111-113, 112
V-HeFT-I and V-HeFT-II, 111
in combination with ISDN, 111, 112-113
hemodynamic effects, 110-111
indications for, 111, 112-113

Hydrochlorothiazide, 113, 114t

Hyperkalemia, 102
ACE inhibitors and, 86t
ARBs and, 86t
CKD patients, 194t
MRAs and, 106, 109

Hyperlipidemia, 160t

Hypertension, 38, 60, 131-133. See also *Diuretics*.
alcohol intake and, 74, 75, 76
chronic pulmonary, 38, 60
heart failure and, 36t, 160t
precapillary pulmonary hypertension, 131-132
pulmonary, agents targeting, 131-133

Hypokalemia, diuretics and, 115

Hyponatremia, 257t
diuretics and, 115
fluid restriction for, 72

Hypotension
ACE inhibitors and, 86t
ARBs and, 86t
hospitalization and, 264, 265t
vasodilators and, 264, 265t

Imaging studies, in diagnosis of HF, 28-29, 29t
2D and Doppler echocardiography, 28, 28t

Implantable electrophysiologic devices.
See *Cardiovascular implantable electrophysiologic devices*.

Implantable hemodynamic monitoring, 231-237
CardioMEMS HF System, 236-237
FDA approval of, 237
CHAMPION trial, 236-237
changes in medications, 236-237, 240
dosage changes in medications, 237, 241
management algorithm, 237, 238-239
COMPASS-HF trial, 231-236

Individuals
individualization of therapy, 255, 274
prognosis, variation in, xiii

Infection
ADHF precipitated by, 259t
implanted electrophysiologic devices (CIEDs) and, 152-153, 154-155

Inotropes, 266-274, 267t
adverse events, 266, 268t-269t
agents available, 267t
indications for, 274
acute decompensated HF-rEF, 274
cardiogenic shock, 274
hospitalized patients with severe systolic dysfunction, 274
low-dose, 266-274, 270-273
not recommended for HF-rEF patients with ADHF, 266

INTERMACS registry of HF stages, 242, 244t-245t, 248

Interventions for HF, 217-252
aortic stenosis, 217-219, 218, 220-223
implantable hemodynamic monitoring, 231-237
left atrial appendage (LAA) closure, 228-231
mechanical circulatory support, 237-246
mitral regurgitation, surgical repair of, 219-228
transcatheter aortic valve replacement (TAVR), 217-219

Iron/iron-binding capacity, 25t

Iron deficiency, 193
algorithm for diagnosis, 201
algorithm for treatment, 202

Iron supplementation, 194-195, 196-200

Ischemic heart disease, comorbid with HF, 160t

Ivabradine, 99-102
 action mechanism, 99
 β -blockers and, xv
 clinical trials, SHIFT, 99, 100-101
 dosage, initiation and up-titration of, xv
 efficacy, 99-102, 100-101
 FDA approval, 99
 guidelines for, xv
 indications for, xix, 99-101
 2016 ACC/AHA/HFSA guidelines, xv
 EMA approved uses, xix
 heart rate reduction in HF-rEF patients with COPD, xix, 101, 173-179, 184t, 185
 vs β -blockers, 99

Kidney disease. See *Chronic kidney disease (CKD)*.

Kinins, 84

Laboratory tests, 23-24, 25t

LCZ696, xviii, 89. See also *Sacubitril/valsartan*.

Left atrial appendage (LAA) closure, 228-231
 AF patients with contraindication for chronic anticoagulation, 228-229, 231
 Kaplan-Meier curves, 229, 232-233
 Kaplan-Meier curves for bleeding, 234-235
 Watchman Device, 229-231, 230

Left ventricular assist devices (LVADs), 237-242. See also *Mechanical circulatory support*.
 patient eligibility criteria, 246, 251t

Left ventricular ejection fraction (LVEF), xviii, 97, 110, 185

Left ventricular (left heart) failure, 38-39, 38
 impaired LV systolic function (HF-rEF), 38

Leukocytes/leukocytosis, 25t

Linagliptin, 165t

Loop diuretics, 115-116. See also *Diuretics*.
 torsemide, 115-116, 118-121
 torsemide vs furosemide, 116, 122t-124t, 125t

LVEF. See *Left ventricular ejection fraction*.

Magnetic resonance imaging (MRI)

Mechanical circulatory support, 237-246
 ECS Guidelines, 246, 248-249
 for patient eligibility, 246, 251t
 HeartMate II device, 242, 243
 INTERMACS registry of advanced HF stages, 242, 244t-245t, 248
 left ventricular assist devices (LVADs), 237-242, 248-249
 patient eligibility criteria, 246, 251t
 REMATCH study, 237
 ROADMAP study, 242-246, 243, 249
 terms used in indications for, 250t
 treatment algorithm and decision guide, 248-249

Meglitinides, 165t

Mental status assessment, 281t, 282-283, 284-285

Metformin, 165t, 166

Metoprolol, 194t

Metoprolol succinate (sustained-release), 96-97

Microalbuminuria, 186

Miglitol, 165t

Milrinone, 266, 267t, 268t-269t
 adverse events, 266, 268t-269t

Mineralcorticoid receptor antagonists (MRAs), 102-109.
 See also *specific agents*.
 action mechanism, 102
 adverse events, 106
 hyperkalemia, 106, 109
 renal dysfunction, 109
 approved agents (eplerone, spironolactone), 102
 clinical trials, 103-109
 EPHEMUS, 103
 RALES, 103
 TOPCAT, 107, 108
 combined with chlorthalidone (diuretic), 115
 discontinuation of, 103
 dosing, 104t-105t
 efficacy, 103-109
 guidelines and recommendations, xviii, 102, 109
 indications for
 HF-pEF, 106-109
 HF-rEF, xviii, 102-106
 HF with CKD, 194t
 monitoring, 103, 109, 110t

- Mitral regurgitation (MR), 133, 219-228
 ADHF precipitated by, 259t
 catheter-based approach, 225
 EVEREST II trial, 225-226
 exercise and, 54
 guidelines on repair, 219-228
 in HF-rEF, 54
 incidence of, 219
 MitraClip device, 133, 225-228, 225
 complications, 228t
 indications for, 226
 meta-analysis of outcomes, 226, 227
 safety data, 226-228
 surgical repair of, 219-228
- Mitral valve regurgitation, 35
- MOOD-HF Study, 287
- MRAs. See *Mineralocorticoid receptor antagonists*.
- Musculoskeletal responses to HF, 56, 60t, 61, 68t
 nitrate supplements and, 76-77
- Myocardial fibrosis, torsemide effects, 120-121
- Myocardial infarction, prior, heart failure and, 36t, 38
- Myocardial injury, 35
 in HF-rEF pathophysiology, 49, 50
- Myocardial ischemia, stress testing for, 30t
- Myocardial remodeling. See *Remodeling*.
- Myocardium
 contractility of, 52-53
 “stretch-squeeze” relationship, 52, 54
- Nateglinide, 165t
- Natriuretic peptides, 88
 A-type (ANP), 51, 88
 augmentation of, 88
 B-type (BNP), 51, 88, 169, 179, 256t
 RAAS activation and, 51, 51
 using to evaluate HF with COPD, 169, 179
- Negative feedback cycles, 49-56, 50, 83-84
 in HF and CKD, 186, 189
- Neprilysin enzyme, xv, 88. See also *ARNI (angiotensin receptor neprilysin inhibitor)*.
- Neprilysin (NEP) inhibitor. See also *Sacubitril/valsartan*.
 angiotensin receptor neprilysin inhibitor (ARNI), xv, 88
 LCZ696 and, xviii, 89
- Nesiritide, 264, 265t, 266-274
 low-dose (“renal-dose”), to enhance effects of diuretics,
 266-274
 vs dopamine (ROSE trial), 266-274, 270-273
- Neuro-hormonal antagonists (ACEi-s, MRAs, β -blockers),
 xviii
- New York Heart Association (NYHA) classification system,
 40-43
 ACC/AHA stages, relationship to, 42
 maximal oxygen uptake, 40, 40
- Nitrates, 109-113
 action mechanism, 109-111
 dietary supplementation, 76-77
 hemodynamic effects, 110-111
 hydralazine, 109-113
- Nitric oxide, 76-77
- Nitroglycerine, 264
- Nitroprusside, 264
 hemodynamic effects of, 111
- Nonpharmacologic management of chronic heart failure,
 71-82. See also *Diet*.
 dietary interventions, 71-77
 environmental conditions, 78-79
 physical activity, 77
- NSAIDs, ADHF precipitated by, 259t
- NYHA classification. See *New York Heart Association (NYHA) classification system*.
- Obesity, 67, 73
 comorbid with HF, 162t
- ONTARGET, 87
- OPTIME-CHF, 266, 268t-269t, 274
- Orthopnea, 255, 258
- Oxygen, maximal consumption of, in HF-pEF, 57
- Oxygen saturation, low, 256t

- Pacing
 cardiac resynchronization therapy, 143, 146, 148-149
 in AF patients, 147-151
 dyssynchrony induced by RV pacing, 147, 150, 150t
 right-ventricular, 150t
- Palliative care, 288-289, 289
- PARADIGM-HF, 89, 92-93
- PARAMOUNT trial, 60-61, 91-96, 96
- Particulate pollution, 79
- Pathophysiology of heart failure, 49-69
 in HF-pEF, 56-61, 64
 cardiac changes, 68t
 comorbidities, 49, 66-67
 musculoskeletal responses, 61, 68t
 physiology: LV volume/pressure, 62-63
 pulmonary responses, 57-60, 68t
 renal responses, 60-61, 67
 in HF-rEF, 49-56, 50
 cardiac performance and end diastolic volume, 52-53
 cardiovascular responses, 51-54, 52-53
 hemodynamic congestion, 50-51
 musculoskeletal responses, 56, 60t
 negative feedback cycles, 49-56, 50, 83-84
 pulmonary abnormalities, 54-55
 RAAS activation, 50, 50, 51, 51
 renal responses, 55-56, 55t, 56t
 salt and water retention, 50, 50
 self-perpetuating process, 51
- Patient phenotypes (“clusters”) in HF, 43, 46-47
- Patient questions, information needed to address, 33
- Patients and families
 discussions about prognoses, 289, 290t
 end-of-life planning, 288-291
 management plan, discussing with, 289-291, 290t
- Peripheral perfusion, assessment of, 23, 24t, 258
- Peripheral vascular disease, heart failure and, 36t
- Pharmacologic management of heart failure, 83-140,
 258-274. See also *specific drugs and drug types*.
 acute decompensated heart failure (ADHF), 255, 258-274
 agents, 84t
 ACEi-s, 83-86
 agents targeting pulmonary hypertension, 131-133, 132t
- Pharmacologic management of heart failure, agents
(continued)
 anti-platelet agents, 125-127
 anti-thrombotic agents, 125-131
 anticoagulants, 127-131
 ARBs, 86-88
 β -blockers, 96-99
 digoxin, 116-117, 126
 diuretics, 113-116, 259-260
 dobutamine, 267t
 dopamine, 266-274, 267t
 hydralazine/nitrates, 109-113
 inotropes, 266-274, 267t
 ivabradine, 99-102
 milrinone, 266, 267t
 morphine, 258-259
 MRAs (mineralcorticoid receptor antagonists), 102-109
 sacubitril/valsartan, 88-96
 vasodilators, 109-113, 262-266, 274
 vasopressin antagonists, 260-262, 263
 of chronic heart failure, 83-140
 classes of agents, 84t
- Phenotypes of HF patients, 43, 46-47
- Phosphodiesterase inhibitors
 indications for, 132t
 milrinone, 266, 267t
- Physical activity, 77. See also *Exercise*.
- Physical examination, 23, 24t
- Pioglitazone, 165t
- Prazosin (Minipress), 111
- Prognosis
 depression and, 283, 286
 discussions with patients and families about, 289, 290t
 individual variation in, xiii
- Prostanoids, 132t
- Psychosocial issues, 37t, 279-294
 cognitive impairment, 281t, 282-283, 284-285
 depression, xix-xx, 283-288
 end-of-life planning, 288-291, 288t
 ESC guidelines on, 280t, 281t
 frailty, 279-282, 280t
- Pulmonary abnormalities, in HF-rEF, 54-55

- Pulmonary congestion, 256t
- Pulmonary edema, 22t
 - acute, patient phenotype, 43
 - hemodynamic patterns in, 39t
- Pulmonary examination, 23, 24t
- Pulmonary function testing, 29-30, 30t
- Pulmonary hypertension
 - agents targeting, 131-133, 132t
 - referral to a HF center, 132
- Pulmonary responses
 - in HF-pEF, 57-60, 68t
 - in HF-rEF, 54-55

- QRS widening, 143, 146
- QT-prolongation, anticancer drugs and, 203

- RAAS. See *Renin-angiotensin-aldosterone system*.
- Race
 - hospitalization rates for HF and, 35, 36t
 - hydralazine, African Americans and, 111-113, 112
- RALES trial, 103
- Ramipril, clinical trials of, 87
- RED-HF trial, 193
- Regurgitation. See *Mitral valve regurgitation*.
- REMATCH study, 237
- Remodeling, 35
 - electrical, 54
 - in HF-rEF, 50, 54
 - negative feedback cycle, 50
 - structural, 54
- Renal dysfunction, 67
 - cardio-renal syndrome, 55, 55t
 - heart failure and, 37t
 - in HF-pEF, 60-61, 67
 - in HF-rEF, 55-56, 55t, 56t
 - mechanisms of, 55-56, 56t
 - pathophysiology of, 55-56, 56t, 58-59
 - renal congestion, 55-56, 58
 - renal inflammation, 58-59
- Renal function
 - glomerular filtration rate, 25t, 104t-105t
 - monitoring with MRAs, 109
 - testing for, 25t

- Renin, increased levels of, 50
- Renin-angiotensin-aldosterone system (RAAS), 50, 50
 - activation of, 50, 50
 - cascade of effects, 85
 - sodium (salt) limitation and, 71
 - activation of natriuretic peptides, 51, 51
 - aldosterone in, 102
 - renin-angiotensin cascade, 85
 - torsemide effects on, 118-119
- Repaglinide, 165t
- Resources for patients, 295-296
- Right heart (Swan-Ganz) catheterization, 31, 39
- Right ventricular failure, 35-38, 38
- Right-ventricular pacing, cardiac effects of, 150t
- Riociguat, 132t
- Rivaroxaban, 130-131
- ROADMAP study, 242-246, 243, 249
- ROSE trial, 266-274, 270-273, 274
- Rosiglitazone, 165t

- Sacubitril
 - action mechanism, 89
 - as LCZ696, xviii, 89
- Sacubitril/valsartan (Entresto), 88-96
 - action mechanism, xv, 89
 - adverse reactions, xv
 - angioedema, xv, 89
 - minimizing risk for, xviii
 - hypotension, xv
 - cautions and contraindications, xv, 89
 - combining with ACEi or ARB, xviii
 - clinical trials, 89-96
 - PARADIGM-HF, 89, 92-93
 - PARAMOUNT, 91-96, 96
 - dosing
 - initiation of therapy, 91, 94-95
 - switching from ACEi-s or ARBs to, 91, 94-95
 - efficacy, 89-96
 - FDA approval, 89
 - guidelines for, xv, 91
 - indications for, xv
 - 2016 ACC/AHA/HFSA guidelines, xv, 91

Sacubitril/valsartan (Entresto), indications for (*continued*)
 HF-pEF, 91
 HF-rEF, 91
 to replace ACEi in HF-rEF patients, xviii, 91, 94
 initiation of, withholding ACEi prior to, xviii
 LCZ696, xviii, 89
 molecular structure, 90
 troponin T-sensitivity, 92, 96
 SADHART-CHF, 287
 Salt limitation (in diet), 71-72, 72t
 Salt retention, 21, 22t, 50, 50
 Saxagliptin, 165t
 Selixigap, 132t
 Sertraline, 287
 SGLT2 inhibitors, 165t, 167-169, 168
 adverse effects of, 169, 176-177
 CV outcomes trials, 178t
 SHIFT trial, 99, 100-101
 Shock
 cardiogenic, 22t, 39t
 hemodynamic patterns in, 39t
 Sildenafil, 132t
 Silent cerebral ischemia (SCI), 282, 283
 Sitagliptin, 165t
 Sleep-related breathing disorders, 23t, 67
 Sodium limitation, 71-72
 conversion factors, 72t
 Sodium retention, ADHF precipitated by, 259t
 SOLVD, 84
 renal function in, 189-190
 Spironolactone, 102
 clinical trials, 103, 106-107
 RALES, 103
 TOPCAT, 107, 108
 dosage, 104t-105t
 indications for, 103, 106, 109
 ST-T waves, 26t
 Staging of heart failure, 33-47. See also *Classification of heart failure*.
 ACC/AHA stages, 40-43, 41t
 INTERMACS registry of stages for advanced HF, 242, 244t-245t
 NYHA classification system, 40-43, 40, 41t, 42
 Statistically significant P-values, xii
 STICHES, 159-161, 164
 “Stretch-squeeze” relationship, 52, 54
 Stroke, heart failure and, 36t, 127
 Substance abuse, 23t, 43
 ADHF precipitated by, 259t
 Sudden cardiac death, 141-143
 incidence of, 142
 Sulfonylureas, 165t
 Surgical treatments. See also *Interventions for HF*.
 aortic stenosis, 217-219, 218, 220-223
 cardiac transplantation, 30, 31, 73, 237
 cardiovascular implantable electrophysiologic devices (CIEDs), 141-158
 implantable hemodynamic monitoring, 231-237
 left atrial appendage (LAA) closure, 228-231
 mechanical circulatory support, 237-246
 mitral regurgitation, surgical repair of, 219-228
 Sympathetic nervous system, 50
 Symptoms of heart failure, 21, 22t, 254-255, 256t-257t
 T waves, 26t
 Tachycardia, 26t, 50
 low cardiac output and, 257t
 milrinone, 268t
 sudden cardiac death and, 141, 142
 Tamponade, MitraClip and, 228t
 Telmisartan (Micardis), 87
 Temperature extremes (environmental), 78-79
 Thiazide diuretics, 113-115
 Thiazolidinediones
 adverse effects of, 161
 in diabetes, 161
 Thromboses: anti-thrombotic agents, 125-131
 Thyroid function tests, 25t
 Tolvaptan, 260-262, 263
 approved uses, 262
 TOPCAT, 107, 108
 Torsemide, 115-116
 effects on myocardial fibrosis, 120-121
 effects on RAAS, 118-119
 potential benefits of, 125t
 vs furosemide, 122t-124t, 125t

Transcatheter aortic valve replacement (TAVR), 217-219
Treatment of heart failure. See also *specific subjects*.
in acute decompensated heart failure (ADHF), 255, 258-274
AV nodal ablation, 147-151, 151
cardiac resynchronization therapy, 143, 146, 148-149
cardiovascular implantable electrophysiologic devices,
141-158
classification and staging systems and, 33-47
patient phenotypes, 43, 46-47
treatment context provided, 43, 44t
goals of, xviii, 255
guidelines for, xiv-xx, 258-259. See also *Guidelines for
heart failure management*.
2016 ESC Guidelines, xiv, xv-xx, 258-259
on psychosocial issues, 280t, 281t
ACC/AHA guidelines, xvi-xviii[t], 258
guideline-directed therapy, xii, xiv
limitations of, xii
neuro-hormonal antagonists (ACEi-s, MRAs,
 β -blockers), xviii
statistical P-values, xii
strength of recommendations and level of evidence,
xvi-xviii[t]
updated guidelines, xiv-xx
interventions for HF, 217-252
aortic stenosis, 217-219
implantable hemodynamic monitoring, 231-237
mechanical circulatory support, 237-246
nonpharmacologic management, 71-82
dietary interventions, 71-77
environmental conditions, 78-79
physical activity, 77
palliative care, 288-289, 289
pharmacologic management, 83-140, 84t
ACEi-s, 84-86
agents targeting pulmonary hypertension, 131-133, 132t
anti-platelet agents, 125-127
anti-thrombotic agents, 125-131
anticoagulants, 127-131
ARBs, 86-88
 β -blockers, 96-99
of chronic heart failure, 83-140

Treatment of heart failure, pharmacologic management
(*continued*)
digoxin, 116-117, 126
diuretics, 113-116, 259-260
dobutamine, 267t
dopamine, 266-274, 267t
hydralazine/nitrates, 109-113
inotropes, 266-274, 267t
ivabradine, 99-102
milrinone, 266, 267t
mineralocorticoid receptor antagonists (MRAs), 102-109
morphine, 258-259
sacubitril/valsartan, 88-96
vasodilators, 109-113, 262-266, 274
vasopressin antagonists, 260-262, 263
psychosocial issues, 279-294
cognitive impairment, 282-283
depression, 283-288
end-of-life planning, 288-291
frailty, 279-282
QRS widening, 143, 146
Tricyclic antidepressants, xx
Troponin T, 92, 96
Two-dimensional echocardiography, 28, 28t
Type 2 diabetes, 161-169, 165t, 170-172

U waves, 26t
Ultrafiltration, 262, 274

Valsartan. See also *Sacubitril/valsartan*.
molecular structure, 90
Vascular resistance, systemic, 50
Vasodilators, 109-113, 262-266, 274. See also *specific drugs*.
ACC/AHA guidelines, 264
blood pressure, concerns about, 264, 265t
choice of agent, 264
hypotension and, 264, 265t
nesiritide, 264, 265t
nitroglycerine, 264
nitroprusside, 264
parenteral, 262-264
use in acute decompensated heart failure, 262-266

Vasopressin antagonists, 260-262, 263
 tolvaptan, 260-262, 263

Ventricle

- left
 - left ventricular assist devices (LVADs), 237-242
 - left ventricular ejection fraction (LVEF), xviii, 97, 110, 185
 - left ventricular failure, 38-39, 38
 - physiology in HF-pEF: LV pressure/volume, 62-63
- right
 - right ventricular failure, 35-38, 38
 - right-ventricular pacing, 150t

Ventricular dysfunction, in heart failure, 52-53, 54

Ventricular remodeling. See *Remodeling*.

Volume overload, 22t, 50

- causes of, 50, 50

Volume status assessment, 23, 24t

Warfarin, 127, 128. See also *Anticoagulants*.

- use with clopidogrel, 130
- Watchman Device as alternative to, 229

Watchman Device, 229-231, 230

Water restriction. See *Fluid restriction*.

Water retention, 50, 50

Weight gain, 23t

Weight loss, recommendation for, 73-74

White blood cell count, 25t